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Introduction {#sec1}
============

The development of ventral midbrain (VM) dopaminergic (DA) neurons involves multiple parallel, controlled processes encompassing many signaling molecules and transcription factors tightly coordinated in order to produce functional midbrain DA (mDA) neurons (reviewed in [@bib7]). Wnt signaling has been shown to play many essential functions in VM DA neuron development both *in vivo* and *in vitro*, by activating both Wnt/β-catenin-dependent and/or -independent pathways ([@bib6], [@bib28]). In brief, *Wnt1*/β-catenin-dependent signaling in the midbrain is responsible for the specification of the mDA progenitor domain, progenitor proliferation, and survival at late stages ([@bib13], [@bib49], [@bib5]). *Wnt5a*/β-catenin-independent signaling is responsible for regulating midbrain morphogenesis, neurogenesis, and mDA precursor differentiation ([@bib4], [@bib5], [@bib13]). Other VM Wnt/β-catenin activators include *Wnt2* responsible for increasing progenitor proliferation ([@bib56]) and *Wnt7a* for progenitor proliferation, neurogenesis, and axon morphogenesis ([@bib18]). Wnt modulators and inhibitors including *Sfrp1/2* have a role in potentiating the Wnt/PCP signal ([@bib31]), and Dickkopf members such as *Dkk1* regulate mDA differentiation and morphogenesis ([@bib51]), while *Dkk3* promotes mDA neuron differentiation ([@bib19]).

The roof plate-specific spondin (RSPO) family of secreted matricellular Wnt modulator proteins (RSPO1-RSPO4) show ∼60% amino acid homology and share similar domain structure ([@bib38]). RSPOs contain a thrombospondin type I repeat domain ([@bib14], [@bib30]) that is shared with spondin 1 (SPON1; floor plate spondin), which promotes neural cell adhesion, neurite outgrowth, and nerve precursor differentiation ([@bib17], [@bib34], [@bib55]). RSPOs also contain two furin-like cysteine-rich domains that are necessary to activate the Wnt/β-catenin pathway ([@bib33]) and to maintain the stem cell compartments in organs such as the intestine, liver, pancreas, kidney, and hair follicle among others ([@bib9], [@bib10], [@bib26], [@bib27], [@bib29]).

RSPOs act synergistically to activate Wnt/β-catenin ([@bib30], [@bib32]) by binding to the leucine-rich repeat-containing G protein-coupled receptor 4, 5, or 6 (LGR4-6) instead of the typical WNT receptors, frizzleds (FZDs), or the co-receptor, low-density lipoprotein receptor-related protein 5 or 6 (LRP5/6) ([@bib12], [@bib21], [@bib37]). Upon RSPO binding to LGR, the transmembrane E3 ubiquitin ligases, ring finger protein 43 (RNF43), or the zinc and ring finger 3 (ZNRF3), bind to RSPO ([@bib15]) and become part of the RSPO-LGR complex ([@bib22], [@bib35]). This prevents RNF43 and ZNRF3 from interacting with the WNT-FZD complex and leads to the ubiquitination and degradation of RSPO-LGR instead of the WNT-FZD-LRP signaling complex, thus increasing Wnt/β-catenin signaling ([@bib39], [@bib60]). However, RSPOs have also been reported to inhibit Wnt/β-catenin signaling ([@bib52]) and to activate Wnt/PCP signaling by binding to the heparan-sulfateproteoglycan, syndecan 4 ([@bib47]), suggesting that their activity may be cell context dependent.

*Rspo2* has been shown to play roles in morphogenesis of the respiratory tract as well as limb development ([@bib11]). Within the nervous system, *Rspo2* expression is regulated by the LIM homeodomain transcription factor, *Lmx1a* ([@bib25]), a transcription factor required for the specification of the midbrain floor plate and mDA neuron development ([@bib3], [@bib16]). In addition, *miR135a2* has been predicted to target *Rspo2* and *Lmx1b.* While deletion of the *Lmx1b* results in reduced Wnt/β-catenin signaling and the mDA progenitor pool ([@bib2]), deletion of *Rspo2* resulted only in a modest decrease in the immunoreactivity of mDA neuron markers, such as TH (tyrosine hydroxylase; the rate-limiting enzyme for dopamine synthesis) and PITX3 (paired-like homeodomain transcription factor 3; a transcriptional regulator of mDA neuron differentiation \[[@bib43], [@bib46]\]). It is thus at present unknown whether the development of mDA neurons can be controlled by proteins of the RSPO family or SPON1 and whether they can control stem cell behavior as described in other tissues.

Here we report that *Rspo2*, but not *Rspo1*, *3*, *4*, or *Spon1*, is dynamically expressed in the VM during the critical time window of mDA neurogenesis. Moreover, analysis of the function of recombinant RSPO2 protein revealed robust positive effects on mDA differentiation that resulted in a 2-fold increase in the number of mDA neurons, not only in primary VM cultures but also in mouse and human embryonic stem cell (ESC) preparations. Thus, our results identify RSPO2 as an efficient factor capable of promoting mDA neuron differentiation in both mouse and human stem cell differentiation protocols. This knowledge can be applied to improve current human ESC-based models and cell replacement strategies for Parkinson disease focusing on the loss of mDA neurons.

Results {#sec2}
=======

Expression of Spondins in the Developing Mouse Midbrain Floor Plate {#sec2.1}
-------------------------------------------------------------------

We first determined the expression of all the roof plate family of Spondins, *Rspo1-4*, and the related floor plate *Spon1* (hereafter collectively referred to as spondins) in the developing VM. A clear differential upregulation of the expression of only *Rspo2* was detected by qPCR at embryonic day 11.5 (E11.5), during mDA neurogenesis and differentiation. All the other spondins either decreased over time or remained relatively constant from E10.5 to E15.5 ([Figure 1](#fig1){ref-type="fig"}A). Immunohistochemistry (IHC) showed diffuse expression of RSPO2 in the midbrain floor plate at E11.5, which later concentrated in patches at E12.5 ([Figure 1](#fig1){ref-type="fig"}B). TruSeq RNA sequencing (RNA-seq) of the VM between E11.5 and E14.5 ([Figure S1](#mmc1){ref-type="supplementary-material"}A) ([@bib57]) confirmed that *Rspo2* is expressed early in mDA development and falls at later stages. This technique also revealed very low expression levels of *Rspo1*, *Rspo3*, and *Rspo4* (less than 1.5 reads per million, [Figure S1](#mmc1){ref-type="supplementary-material"}B). In contrast, *Rspo2* and *Spon1* were expressed at one or two orders of magnitude higher, respectively ([Figure 1](#fig1){ref-type="fig"}C). The expression pattern of *Rspos* in the VM were also examined in the Allen Developing Mouse Brain Atlas ([@bib1]), where we found that *Rspo2* is clearly expressed in mDA progenitors adjacent to mDA neurons, identified by *Th* expression in the marginal zone ([Figures 1](#fig1){ref-type="fig"}D and [S1](#mmc1){ref-type="supplementary-material"}C, arrowheads). Lower expression of *Rspo2* was detected at E13.5, while other RSPOs were undetectable in the VM, but present in other structures ([Figures S1](#mmc1){ref-type="supplementary-material"}D and S1E). Notably, *Rspo2* was also detected in a subset of mDA neurons of the *substantia nigra pars compacta* region, at postnatal day 56 ([Figure S1](#mmc1){ref-type="supplementary-material"}F) ([@bib40]). Moreover, analysis of our single-cell RNA-seq dataset of the developing mouse VM from E11.5 to E18.5 ([@bib42]) revealed that *Rspo2* is significantly expressed in early neural progenitor cells and medial neuroblasts, two cells in the mDA neuron lineage, while *Spon1* was expressed in radial glia-like cells ([Figure 1](#fig1){ref-type="fig"}E). Other spondins were either undetected, expressed uniformly or in varying cell types at low copy number ([Figure S1](#mmc1){ref-type="supplementary-material"}G). We thus can conclude that *Spon1* and *Rspo2* are expressed at significant levels in the midbrain floor plate, *Rspo2* being specifically expressed in cells of the mDA lineage and dynamically regulated during mDA neurogenesis.Figure 1Expression of Spondins in the Developing Ventral Midbrain(A) Expression of *Rspo*(*1--4*) and *Spon1* measured by qPCR in VM tissue from E10.5 to E15.5. Statistical analysis compared with E11.5 for Rspo2, the rest compared with E10.5. ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001 by ANOVA. Data presented as means ± SEM measured in a.u., normalized to starting time point, E10.5.(B) Detection of RSPO2 and TH in the VM by IHC, at E11.5 and E12.5. Dashed lines delineate the ventricular cavity. Scale bars, 100 μm.(C) Expression levels of *Rspo2* and *Spon1* by TruSeq RNA-seq analysis of VM tissue obtained from *TH-GFP* mice over time points E11.5 to E14.5 ([@bib57]). See also [Figure S1](#mmc1){ref-type="supplementary-material"}A.(D) E11.5 mouse VM *in situ* hybridization (image data from Allen Institute for Brain Science: Allen Developing Mouse Brain Atlas) for *Rspo2* (solid arrowheads) and *Th* (open arrowheads) as a reference. Sagittal sections through the midline (upper panels) and lateral (lower panels). Scale bars, 200 μm.(E) Violin plots generated from single-cell RNA-seq data of the developing mouse VM. *Rspo2* and *Spon1* expression levels are shown across all known cell types. Right axis shows absolute molecule counts. Gray, enriched over baseline with posterior probability \>99.8%. Cell types with enriched expression: mNProg, neuronal progenitor; mNbM, neuroblast medial; mNbML2, neuroblast mediolateral 2; mRgl1-3, radial glia-like cells 1-3. For the rest of the nomenclature, see [@bib42].See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

Expression of Spondin Receptors in the Developing Mouse Midbrain Floor Plate {#sec2.2}
----------------------------------------------------------------------------

The expression of *Lgr4-6* and associated receptors were first examined in bulk RNA-seq data obtained from the developing VM. We found that *Lgr6* is expressed at very low levels and that *Lgr4* and *Lgr5* were not developmentally regulated between E11.5 and E14.5 ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Single-cell RNA-seq analysis revealed significant expression of both receptors in basal plate cells, such as radial glia 2 (*Lgr4* and *Lgr5*) as well as lateral neuroblast 2 and GABA2 neurons (*Lgr4*) ([Figure S2](#mmc1){ref-type="supplementary-material"}B). This result was confirmed by IHC, which revealed the presence of immunoreactive cells in the basal plate ([Figure S2](#mmc1){ref-type="supplementary-material"}C). However, IHC for LGR5 revealed a more dynamic distribution of this protein than expected ([Figure 2](#fig2){ref-type="fig"}). At E11, individual LGR5^+^ cells sparsely lining the ventricle were detected ([Figure 2](#fig2){ref-type="fig"}A, arrowheads). At E11.5, LGR5 IHC was clearly detected in their processes, which co-localized with the radial glia marker Nestin (NES) ([Figure 2](#fig2){ref-type="fig"}B), but its expression decreased in cell bodies lining the ventricle ([Figure 2](#fig2){ref-type="fig"}B, arrowheads). At E12.5, the levels of LGR5 decreased, resulting in less LRG5^+^ radial glia processes in the basal plate than in the floor plate ([Figure 2](#fig2){ref-type="fig"}C), and very few LRG5^+^ cell bodies ([Figure 2](#fig2){ref-type="fig"}C, arrowhead). Analysis of the expression of the two additional RSPO receptors, revealed low levels of *Rnf43*, peaking at E11.5--E12.5, and very low or undetectable levels of *Znrf3* by either bulk or single-cell RNA-seq ([Figures S2](#mmc1){ref-type="supplementary-material"}D and S2E). Receptors of SPON1, APP, and APOER2/LRP8 ([@bib23], [@bib24]) were also expressed, as observed through the RNA-seq data and *in situ* hybridization images ([Figures S2](#mmc1){ref-type="supplementary-material"}F and S2G). Thus, our results show that the developing midbrain expresses Spondins receptors, suggesting that the ligands may play a role in development.Figure 2Identification of LGR5-Positive Cells in Early VM Development(A) IHC showing LGR5^+^ cells lining the ventricle in the VM at E11. Right panel shows a higher magnification of LRG5^+^ cells in the left panel, identified with arrowheads. Scale bars, 50 μm (left panel) and 10 μm (right panel).(B) LGR5 IHC at E11.5 showed less positive cells bodies (arrowheads) and a strong staining radial processes co-stained with Nestin (NES), visible at intermediate (upper right) and higher magnification (lower right). Scale bars, 100 and 20 μm (lower left panel).(C) LGR5 and SOX2 IHC in the VM at E12.5. Arrowhead shows sporadic double-positive cells in the ventricular zone (VZ), while LRG5 fibers are found to be more restricted to the VM domain. Dashed lines delineate the floor plate. Scale bars, 100 μm (upper panels) and 20 μm (lower panels).See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

RSPO2, but Not RSPO1 or SPON1, Promotes the Differentiation of Neuroblasts into mDA Neurons {#sec2.3}
-------------------------------------------------------------------------------------------

We next examined the function of the two spondins expressed at higher levels during VM development, RSPO2 and SPON1. E11.5 VM primary cultures were treated for 3 days with recombinant RSPO1, RSPO2, or SPON1 ([Figure 3](#fig3){ref-type="fig"}A). We first found that the total number of cells, identified by nuclear DAPI staining, or the total number of neurons in the culture, visualized by immunocytochemistry (ICC) with the pan-neuronal marker βIII-tubulin, did not change in the culture ([Figures 3](#fig3){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}A). Accordingly, we did not detect any change in cell death, as assessed by active caspase-3 staining, or in the number of proliferating cells as determined by Ki67 ([Figures 3](#fig3){ref-type="fig"}C and 3D, respectively). We next examined whether the proportion of cells in the mDA lineage changed with the treatments. Postmitotic cells in the mDA lineage (neuroblast and neurons), marked by the presence of NR4A2 (nuclear receptor subfamily 4, group A, member 2; also known as Nurr1), showed no significant difference between the treatments ([Figure 3](#fig3){ref-type="fig"}F). However, in cultures treated with recombinant RSPO1 or RSPO2, but not with SPON1, a significant increase in the number of TH^+^ mDA neurons was detected (∼1.75- and ∼2.5-fold increase, respectively) treatment ([Figures 3](#fig3){ref-type="fig"}G and 3E). We then examined whether this effect was due to an increase in the proportion of postmitotic NR4A2^+^ neuroblasts that differentiate into TH^+^ mDA neurons and found that this was the case for RSPO2 ([Figure 3](#fig3){ref-type="fig"}H). We also performed expression analysis of DA genes by qPCR in RSPO2-treated cultures ([Figure S3](#mmc1){ref-type="supplementary-material"}B) and found a significant increase in *Aldh1a1* expression, a marker for the *substantia nigra pars compacta* and VTA type 2 cell types ([@bib42]), but no changes in *Otx2*, *Lmx1a*, *Nr4a2*, *En1*, or *Pitx3*, suggesting a very specific role of RSPO2 in late differentiation. Combined, our results indicate that RSPO2 is the only spondin capable of promoting the development of mDA neurons, and that it does so by promoting the differentiation of NR4A2^+^ neuroblasts into a subset of TH^+^ mDA neurons.Figure 3RSPO2 Promotes Midbrain Dopaminergic Neurons Differentiation in Primary Cultures(A) Schematic representation of the mouse primary cell culture protocol.(B) Quantification of the total cell numbers (DAPI) and proportion of neurons (βIII-tubulin/DAPI) normalized to control (Vehicle).(C) Quantification of ongoing cell death, measured by active caspase-3 ICC (aC3^+^/DAPI), showed no difference compared with Vehicle.(D) Quantification of KI67 ICC (KI67^+^/DAPI) showed no difference compared with Vehicle.(E) ICC staining showing and increase in TH^+^ neurons compared with DAPI after RSPO2 treatment, but not RSPO1 or SPON1. Scale bars, 50 μm.(F) Quantification of postmitotic cells in the DA lineage, measured by NR4A2 ICC, showed no difference compared with Vehicle.(G) Bar plots showing that RSPO2 treatment increases the total number of TH^+^ cells (TH/DAPI), compared with control (Vehicle).(H) Normalized ratio of TH^+^ cells/NR4A2^+^ cells revealed an increase in the proportion of postmitotic dopaminergic cells (NR4A2^+^) becoming mDA neurons (TH^+^).(I) ICC staining of cells treated with various Wnt signaling pathway modifiers, stained with TH and βIII-tubulin. Scale bars, 50 μm.(J) Quantification of TH^+^ cells in various treatments from (I) as compared with Vehicle.All data normalized to control (Vehicle) presented as means ± SEM. n = 3, t test; ^∗^p \< 0.05, ^∗∗^p \< 0.01. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

We also examined whether the activity of RSPO2 in primary cultures could be potentiated or inhibited by co-treatment with RSPO1 or modulators or Wnt signaling. Surprisingly we found that RSPO1 reduced the increase in the number of TH^+^ neurons by RSPO2 ([Figures 3](#fig3){ref-type="fig"}I and 3J), indicating that RSPO1 and RSPO2 have clearly distinct activities. Moreover, we found that co-treatment of primary cultures with either WNT5A or Dkk1, both of which inhibit Wnt/β-catenin signaling in the VM (for review see [@bib6]), reduced the effects of RSPO2 on the number of TH^+^ cells ([Figures 3](#fig3){ref-type="fig"}I and 3J). This result suggests that the effect of RSPO2 on mDA neurons involves, at least partially, the activation of Wnt/β-catenin signaling.

To rule out an early effect of spondins on mDA progenitors, we examined earlier stages of mDA neuron development in mouse ESCs. We used a 14-day differentiation protocol and treated the cultures with either SPON1 or RSPO2 between day 5 and 11 ([Figure 4](#fig4){ref-type="fig"}A). However, neither SPON1 nor RSPO2 showed any significant effect on cell proliferation or cell death as shown by active caspase-3 and Ki67 immunostainings ([Figures 4](#fig4){ref-type="fig"}B and 4C). Similar to the primary cultures, the number of postmitotic NR4A2^+^ neuroblasts did not change by SPON1 or RSPO2 treatment ([Figure 4](#fig4){ref-type="fig"}D), and a significant 1.8-fold increase in TH^+^ neurons was detected ([Figures 4](#fig4){ref-type="fig"}E and 4F). Although, SPON1 induced a significant 30% decrease in the number of TH^+^ cells ([Figures 4](#fig4){ref-type="fig"}E and 4F). Analysis of the proportion of TH^+^ neurons being generated from NR4A2^+^ neuroblasts in differentiated mouse ESCs also revealed a modest decrease in DA differentiation by SPON1 and a clear increase by RSPO2 ([Figure 4](#fig4){ref-type="fig"}G). These results thus confirm the specific role of RSPO2 in promoting the late differentiation of mDA neuroblasts into neurons in the developing mouse VM.Figure 4RSPO2 Promotes the Dopaminergic Differentiation of Mouse ESCs(A) Cartoon showing the protocol for the differentiation of mouse ESCs into mDA neurons and the time line (d, days) of spondin treatment, between days 5 and 11.(B) Quantification of proliferation (KI67) in areas undergoing neurogenesis (βIII-tubulin^+^) as assessed by ICC, normalized to control.(C) Quantification of ongoing cell death by active caspase-3 (aC3) ICC in βIII-tubulin^+^ areas.(D) ICC for NR4A2 and βIII-tubulin after 14 days *in vitro* and bar plots showing no difference in the number of NR4A2^+^ cells per βIII-tubulin area. Scale bars, 50 μm.(E) ICC staining for TH and βIII-tubulin after 14 days *in vitro* in vehicle-, SPON1-, and RSPO2-treated cultures. Scale bars, 50 μm.(F) The number of TH^+^ cells per βIII-tubulin area by ICC, normalized to control, increased by RSPO2 treatment and decreased by SPON1.(G) The proportion of NR4A2^+^ cells that become TH^+^ increased by RSPO2 treatment and decreased by SPON1.All data normalized to control (Vehicle) presented as means ± SEM. n = 3, t test; ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.

RSPO2 Promotes the Differentiation of Human ESCs into DA Neurons and mDA neurogenesis {#sec2.4}
-------------------------------------------------------------------------------------

We next examined whether the function of RSPO2 is conserved in human DA neuron development and whether RSPO2 could be used to improve the differentiation of human ESCs into mDA neurons. We first investigated the expression of *RSPO2* and *SPON1* in our single-cell RNA-seq dataset from human VM development ([@bib42]). Interestingly, we found higher levels of expression of *RSPO2* and *SPON1* in the human VM compared with mouse and significant differences in the cell types expressing them. While *RSPO2* is exclusively expressed in radial glia type 1 (hRgl1), *SPON1* is exclusively expressed in radial glia type 3 (hRgl3, [Figure 5](#fig5){ref-type="fig"}A). Analysis of the expression of the Rspo receptors by single-cell RNA-seq revealed very low levels of *LGR4-6*, *RNF43*, and *ZNRF3* (mean molecules/cell) and higher levels of *LGR5* in different cells, including a floor plate progenitor (hProgFPM, [Figure S4](#mmc1){ref-type="supplementary-material"}A), a cell type thought to give rise to mDA neurons ([@bib42]). We thus decided to examine the possible role of RSPO2 on mDA neuron development in human ESC cultures.Figure 5Role of RSPO2 in Differentiation of Human ESCs(A) Violin plots generated from single-cell RNA-seq data of the developing human VM. *RSPO2* and *SPON1* expression levels are shown across all cell types in the human VM. Right axis shows absolute molecule counts. Gray, enriched over baseline with posterior probability \>99.8%. Cell types with enriched expression: hRgl1,3, radial glia-like cells 1,3. For the rest of the cell-type nomenclature, see [@bib42].(B) Protocol for the dopaminergic differentiation of human ESCs.(C) Human ESC cultures after 28 days stained for various DA lineage markers: EN1, OTX2, TH, and ALDH1A1. Scale bars, 50 μm.(D) Expression of DA markers (*OTX2*, *NR4A2*, *EN1*, *PITX3*, and *ALDH1A1*) by qPCR between Vehicle- and RSPO2-treated cultures after 28 days (unpaired t test, n = 3, ^∗^p \< 0.05, ^∗∗^p \< 0.01).(E) Human ESC cultures after 28 days stained for markers of apoptosis (aC3), proliferation (KI67), markers of DA lineage (NR4A2 and TH). Scale bars, 50 μm.(F) The number of apoptotic cells (aC3^+^/DAPI) was no modified by RSPO2 treatment.(G) The number of proliferating cells (KI67^+^/DAPI) was the same in both conditions.(H) The number of NR4A2^+^ cells were not significantly different in RSPO2-treated and control cultures (t test, n = 3, p = 0.09).(I) A significant increase in the total number of DA neurons (TH^+^/DAPI) was detected in RSPO2-treated human ESC cultures (t test, n = 3, ^∗^p = 0.01).(J) RSPO2 treatment increases the proportion of NR4A2^+^ cells that become TH^+^ in human ESC cultures (t test, n = 3, ^∗^p = 0.02).(K) RSPO2 increases DA neurogenesis in human ESC cultures, as assessed by the incorporation of EdU in TH^+^ cells at day 28, arrowheads. Scale bars, 50 μm.(L) Quantification of the number of EdU/TH double-positive cells showed that RSPO2 significantly increases DA neurogenesis in human ESC cultures (t test, n = 3, ^∗^p = 0.03).See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

Human ESCs were differentiated for 28 days as described recently ([@bib45]), using a protocol that includes the use of GSK3β inhibitors to enhance the induction of human midbrain floor plate (for review see [@bib7]). Human ESCs were treated with recombinant RSPO2 from day 14 to 28 ([Figure 5](#fig5){ref-type="fig"}B) and characterized by ICC and qPCR with various mDA markers ([Figures 5](#fig5){ref-type="fig"}C and 5D). While no change was detected for *OTX2*, *NR4A2*, or *EN1*, we observed a significant increase in *PITX3* and *ALDH1A1* expression. We also found that the levels of ALDH1A1 protein increased by RSPO2 treatment, complementing thus the previous finding of decreased levels in *Rspo2*^*−/−*^ mice ([@bib25]). Also, in line with both our primary and mouse ESC cultures, we found that RSPO2 induced no significant differences in the total number of cells (DAPI), cell death (active caspase-3), or proliferation (Ki67) in the human ESC cultures ([Figures 5](#fig5){ref-type="fig"}E--5G). Notably, quantification of the number of postmitotic cells in the DA lineage revealed no significant difference in the number of NR4A2^+^ cells ([Figures 5](#fig5){ref-type="fig"}E and 5H), but a significant ≈1.8-fold increase in the number of TH^+^ neurons treated with RSPO2 ([Figures 5](#fig5){ref-type="fig"}E and 5I). A significant ≈1.2-fold increase in the proportion of NR4A2^+^ cells that became TH^+^ was detected ([Figure 5](#fig5){ref-type="fig"}J), suggesting that RSPO2 also promotes the differentiation of neuroblasts into mDA neurons. However, this increase was not sufficient to explain the ≈1.8-fold increase in TH^+^ cells, and suggested the involvement of an additional upstream mechanism. To mark proliferating progenitors, we performed a 5-ethynyl-2\'-deoxyuridine (EdU) pulse-chase experiment and examined whether they undergo neurogenesis as identified by the presence of cells double-positive for EdU and TH. Our results show that RSPO2 induced a significant increase in the EdU^+^ cells that undergo neurogenesis and become TH^+^ ([Figures 5](#fig5){ref-type="fig"}K and 5L). Thus, our data indicate that RSPO2, in addition of promoting the differentiation of neuroblasts into mDA neurons in mouse and human, it promotes mDA neurogenesis in human ESC cultures.

Discussion {#sec3}
==========

In this study we examine the expression and function of the extracellular matrix (ECM) proteins of the RSPO family and of SPON1, in the mouse and human VM and ESCs. Our analysis revealed that *RSPO2*, *SPON1*, and *LGR5* are the most significantly expressed spondins and receptors in the VM in both the developing mouse and human VM. However, we identified substantial differences in the cell types expressing spondins. In the mouse, *Rspo2* was found in neuronal progenitors and neuroblasts and *Spon1* in radial glia 1--3; whereas, in the human VM, *RSPO2* and *SPON1* were exclusively expressed in radial glia 1 and 3, respectively. An additional difference between the two species was that human *RSPO2* was expressed in earlier cell types (hRgl1), compared with mouse *Rspo2*, which was expressed in a rapid amplifying type of progenitor (mNProg) and the medial postmitotic neuroblast (mNbM) ([@bib42]). In agreement with this, we found an earlier function of RSPO2 to promote mDA neurogenesis in human ESCs and a shared late function of RSPO2 in mouse and human, to promote the differentiation of postmitotic neuroblasts into mDA neurons. Unlike other systems in which RSPOs control stem cell or progenitor maintenance ([@bib39]) and SPON1 regulates differentiation ([@bib55]), we did not observe any effect of RSPOs on the number of Ki67^+^ cells or the total number of EdU^+^ cells in human ESC cultures, or of SPON1 to promote differentiation. This is not totally surprising as the midbrain floor plate expresses genes otherwise present in completely different compartments (i.e., roof plate genes, such as *Lmx1a*, *Msx1*, *Wnt1*, and *Rspo2*, together with floor pate genes such as *Shh*, *Foxa2*, *Wnt5a*, and *Spon1*), resulting in different regulatory networks and functions compared with other brain regions or structures. One such example is the presence of neurogenesis in the midbrain floor plate, which represents an exception to the entire neural tube. Notably our results indicate that roof plate RSPO2, as other "roof plate factors" in the VM (i.e., *Lmx1a*, *Msx1*, and *Wnt1;* see [@bib7] for review) also regulates mDA neurogenesis.

Understanding human mDA neuron development *in vivo* and implementing such knowledge to protocols for the differentiation of human ESCs into mDA neurons is currently considered as the basis for refining and improving existing protocols to prepare cells for cell replacement therapy. In the past, the implementation of correct levels of Wnt signaling for the specification of midbrain floor plate progenitors has been critical for the development of protocols allowing the transplantation of mDA progenitors capable of efficiently differentiating into functional mDA neurons *in vivo* ([@bib36], [@bib45]). These protocols are still susceptible to improvement by implementing new factors and knowledge, such as additional components of the Wnt signaling pathway recently reported in the developing mouse and human VM ([@bib58]) or the Wnt modulator that we hereby report, RSPO2. As an ECM protein, RSPO2 may function to define, together with other ECM proteins, the niche where human mDA neurogenesis takes place. Indeed, our results indicate that by manipulating the extracellular compartment it is possible to control essential intracellular functions such as mDA neurogenesis and differentiation in human ESC cultures. Moreover, RSPO2 may also play a role in mDA neuron subtype specification, as suggested by the increase in *ALDH1A1* in mouse and human cell expression by RSPO2 treatment (our results) or the decrease in its protein levels in RSPO2^−/−^ mice ([@bib25]). While much attention has been devoted to the role of transcription factors and morphogens in development and stem cell biology, only recently have we started to implement the knowledge of what can be considered as the third pillar of development: the ECM. Indeed, ECM proteins are gaining increasing interest as the accrued knowledge of their diversity (reviewed in [@bib44]) and functions begin to accumulate ([@bib20], [@bib41], [@bib59]). In this context, our study identifies RSPO2 as a matricellular component capable of promoting mDA neurogenesis and differentiation. Our results thus pave the way for RSPO2 to be used to improve current human ESC preparations for regenerative medicine or drug discovery for Parkinson disease.

Experimental Procedures {#sec4}
=======================

Animals {#sec4.1}
-------

Wild-type (WT) CD-1 (Charles River, Germany) or WT Swiss (Janvier Labs) mice were mated overnight, and the noon of the day of a plug was considered E0.5. Mice were shipped as pregnant females, and then housed and treated in accordance with the guidelines of the local ethics committee (Stockholm\'s Norra Djurförsöksetisks Nämd. Ethical numbers N145/09, N273/11, N326/12, and N158/15).

Tissue Collection {#sec4.2}
-----------------

After CD-1 mice were killed and embryos collected at different stages, embryonic heads were fixed in 4% paraformaldehyde (PFA) for at least 6 hr at +4°C. Then tissue was washed briefly in PBS and processed to 30% sucrose/PBS solution overnight at +4°C. Tissue was then embedded in O.C.T. (TissueTek) and stored at −80°C until sectioning. Sectioning was performed on a Leica cryostat at 16 μm sections used for IHC analysis.

qPCR {#sec4.3}
----

### Mice {#sec4.3.1}

RNA was isolated from dissected WT CD-1 mice VM from various time points. RNA was extracted using RNeasy Mini Kit (QIAGEN). SYBR green real-time qPCR assay was performed as described previously ([@bib50], [@bib53]).

### Mouse Primary Culture {#sec4.3.2}

Total RNA was isolated using RNeasy Kit (QIAGEN), and cDNA was made with cDNA SuperScript II Reverse Transcriptase Kit (Thermo Fisher Scientific). Specific genes were amplified using Fast SYBR Green Master Mix Kit (Thermo Fisher Scientific). Real-time PCR was performed using fast protocols on a 7500 Fast Real-Time PCR system (Thermo Fisher Scientific). GAPDH was used to normalize the expression of mRNA.

### Human ESC Culture {#sec4.3.3}

Total RNA was extracted from cells at day 28 of culture using the NucleoSpin RNA extraction kit (Macherey-Nagel, cat. no. 740955.10) as per the manufacturer\'s instructions. Quantity and quality of RNA was determined using a NanoDrop Lite Spectrophotometer (Thermo Fisher Scientific). cDNA was synthesized from 500 ng of RNA using SuperScript II Reverse Transcriptase (Invitrogen). SYBR green (QIAGEN) qPCR assays were performed using a LightCycler 480II (Roche) and primers purchased from Sigma (sequences in table). A 5-fold serial dilution standard curve was generated for each primer to generate efficiency curves and relative expression levels were obtained using the Pfaffl method ([@bib48]). HPRT was used as the housekeeping gene.

Primer sequences in [Table S1](#mmc1){ref-type="supplementary-material"}.

RNA-Seq Datasets and Gene Expression Profiles {#sec4.4}
---------------------------------------------

Gene expression data were obtained through previous datasets. For tissue TruSeq datasets, see [@bib57], and for single-cell RNA-seq datasets see [@bib42].

Primary Cell Culture {#sec4.5}
--------------------

Plates were coated with poly-D-lysine and VMs were dissected out from E11.5 WT embryos into ice-cold PBS. VMs were dissociated by trituration using flame-polished glass Pasteur pipettes. Cells were plated at a density of 150,000 cells/cm^2^. They were grown in N2 medium (1:1 F12:MEM, HEPES, N2 supplement, and glutamine; Thermo Fisher Scientific) with additional 6 mg/mL glucose and 3 mg/mL AlbuMAXI BSA. Cells were treated with for 3 days with different recombinant proteins (recombinant human F-spondin protein 80 ng/mL \[cat. no. 3135-SP\], recombinant human R-spondin 2 protein 160 ng/mL \[cat. no. 3266-RS\], recombinant mouse R-spondin 1 protein 160 ng/mL \[cat. no. 3474-RS\], recombinant mouse Dkk-1 protein 100 ng/mL \[cat. no. 5897-DK\], and recombinant human/mouse Wnt-5a protein 100 ng/mL \[cat. no. 645-WN\], all resuspended in 0.1% BSA/PBS; R&D Systems) or vehicle (0.1% BSA/PBS). Cells were then fixed with 4% PFA and processed for staining.

Mouse ESC Culture {#sec4.6}
-----------------

Mouse ESC (R1) cultures were co-cultured with immortalized PA6 feeder cells. Differentiation of mouse ESCs was done following a 14-day *in vitro* protocol ([@bib8]). Mouse ESCs were maintained in proliferation medium (Knockout-DMEM, 15% Knockout Serum Replacement, 2 mM L-glutamine, 10,000 U/mL penicillin/streptomycin \[all from Life Technologies\], 1% non-essential amino acids \[VWR\], 0.1 mM β-mercaptoethanol \[Sigma\], and 1,000 U/mL leukemia inhibitory factor \[LIF\] \[ESGRO; Chemicon/Millipore\]). Mouse ESCs were plated (150 cells/cm^2^) on a confluent mitomycin C-treated PA6 feeder cell layer in 24-well plates in proliferation medium without LIF. At day 5, sonic hedgehog (SHH) (200 ng/mL) and fibroblast growth factor 8 (FGF8) (25--100 ng/mL) were added to the medium. After 8 days, N2 medium was used in the presence of SHH, FGF8, and basic FGF (10 ng/mL). From day 11 to 14, N2 medium containing ascorbic acid (AA) (200 μM) (Sigma), brain-derived neurotrophic factor (BDNF) (20 ng/mL) (R&D Systems), and glial cell line-derived neurotrophic factor (GDNF) (10 ng/mL) (R&D Systems) was used. Treatments with recombinant spondins or vehicle started at day 5 and lasted up until day 11, concentrations the same as primary cultures. Cells were then fixed with 4% PFA and processed for staining.

Human ESC Culture {#sec4.7}
-----------------

Undifferentiated RC17 ESCs (passages 33--54, Roslin Cells, hPSC reg. no. RCe021-A) were maintained in E8 medium (A1517001) on Geltrex (1%, 12760021)-coated plates and passaged weekly with EDTA (0.5 mM). To start differentiation (day 0), human ESC colonies were detached using EDTA (0.5 mM) and placed in non-treated 60-mm culture dishes in differentiation medium consisting of DMEM:F12/Neurobasal (1:1), N2 supplement (1:100), B27 supplement (1:50), SB431542 (10 μM, Tocris Biosciences), rhnoggin (100 ng/mL, R&D Systems), SHH-C24II (200 ng/mL, R&D Systems), and CHIR99021 (0.9 μM, Tocris Biosciences). Medium was changed once on day 2. The resultant embryoid bodies were collected on day 4 and placed on polyornithine (PO)-, fibronectin (Fn)-, and laminin (Lm)-coated plates in reduced N2 (1:200) and B27 (1:100) condition. Growth and patterning factors were removed on day 9 with the cultures kept in DMEM:F12/Neurobasal (1:1), N2 supplement (1:200), and B27 supplement (1:100). On day 11 of differentiation, the cell clusters were dissociated to single cells with accutase and replated onto dry PO/Fn/Lm-coated plates in Neurobasal, B27 (1:50), BDNF (20 ng/mL), GDNF (10 ng/mL), AA (200 μM), and db-cAMP (0.5 mM, Sigma). From day 14, cultures were treated with RSPO2 (1 μg/mL, R&D Systems) up until day 28, when they were fixed in 3.7% PFA for 30 min. EdU pulse was administered on day 23 for 24 hr to capture all the dividing cells. Cells were then fixed 4 days later on day 28. All culture reagents are from Invitrogen unless otherwise stated here or previously.

IHC/ICC {#sec4.8}
-------

Cells and tissue were fixed in 4% PFA, washed in PBS and blocked in PBTA (PBS, 5% normal goat/donkey serum \[Jackson ImmunoResearch\], 0.1% Triton X-100, and 1% BSA) for 1 hr at room temperature (RT). Primary antibodies were diluted in 0.1% Triton X-100 and 1% BSA/PBS, and incubations were carried out overnight at 4°C.

Antibodies used were: βIII-tubulin (1:1,000, Promega, G7121), cleaved caspase-3 (1:200, Cell Signaling Technology, 9661S), NR4A2 (1:100, Santa Cruz, sc-991), TH (1:1,000, Millipore, AB152), TH (1:1,000, Pel-Freez, P40101), NES (1:500, BD Biosciences, 556309), LGR5 (1:200, Atlas Antibodies, HPA012530), LGR4 (1:50, Santa Cruz Biotechnology, sc-292344), RSPO2 (1:500, Atlas Antibodies, HPA025764), SOX2 (1:200, R&D Systems, MAB2018), Ki67 (1:200, Thermo Fisher Scientific, MA5-14520), EN1 (Abcam, ab70993), OTX2 (R&D Systems, AF1979), ALDH1A1 (Abcam, ab23375), and click-iT EdU (Invitrogen, C10337). Corresponding secondary antibodies were Alexa Fluor Dyes (Invitrogen) (1:1,000) and incubated at RT for 1 hr. Cells were counterstained with DAPI (Thermo Fisher Scientific, D1306) or Hoechst 33258 (Sigma). Cells were then washed and kept in PBS and sections were washed and mounted with Mounting Medium (Dako).

IHC/ICC were captured on an Olympus FV1000 confocal microscope, a Zeiss LSM510 confocal microscope, or a Zeiss Axioplan microscope. Human ESC images were captured on either an operetta high-content imaging system (PerkinElmer) or an SP8 confocal microscope (Leica). Human ESCs were counted using an automated software package (Columbus). Images and figure layouts were processed in FIJI ([@bib54]), Adobe Photoshop, and Adobe Illustrator.

Cell Counts and Statistical Analyses {#sec4.9}
------------------------------------

All experiments were performed as technical duplicates (two wells per treatment) and three independent biological replicates. Analysis of images was performed from at least five images of each well. For mouse ESC cultures, cells were counted within a βIII-tubulin area (defined as an area just outside of cell clusters where nuclei could be distinguished) with the aid of FIJI image processing software ([@bib54]). Statistical test performed include two-tailed t test and/or ANOVA, deviations are SDs unless otherwise stated.

Author Contributions {#sec5}
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